Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.
Ambulatory Care Pharmacy (BCACP) June 24th 2026
Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines and superior for each of the 9 serotypes unique to Capvaxive.
Cardiology September 16th 2025
Cleveland Clinic Journal of Medicine (CCJM)
The 2022 ACIP recommendations introduce new pneumococcal conjugate vaccines and simplified dosing schedules, aiming to enhance prevention of invasive pneumococcal disease while improving guideline implementation in clinical practice.
Allergy & Immunology July 31st 2024
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS